Proactiveinvestors recommends
Additional Information
Market: NASDAQ
Sector: Pharmaceuticals
EPIC: AVII
Latest Price: 1.00  (6.30% Ascending)
52-week High: 2.14
52-week Low: 0.54
Market Cap: 135.71M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
AVI BioPharma
www.avibio.com

AVI BioPharma, Inc. is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid based drugs targeting a range of diseases.

Full AVI BioPharma profile here
Pdf

AVI BioPharma Receives Patent For RNA-based Therapeutics

8th Sep 2010, 8:41 pm
AVI BioPharma Receives Patent For RNA-based Therapeutics

AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it has been granted a U.S. patent covering the use of phosphorodiamidate morpholino based oligomers (PMOs) as antibiotics.

PMOs are synthetic molecules based on a fundamental redesign of the natural nucleic acid structure of deoxyribonucleic acid (DNA) and RNA.

AVI’s PMO-based compounds differ from traditional antibiotics in that instead of targeting proteins, it targets microbial ribonucleic acids (RNAs) to inhibit protein expression at the gene level.

In in-vitro studies, AVI's PMO-based compounds have demonstrated bactericidal activity against both antibiotic susceptible and resistant bacteria, and to date have not shown cross-resistance to other classes of antibiotics, said the company.

Advanced generation PMO-based antisense chemistries have also been developed by AVI and are being applied to the discovery and development of new drug candidates.

AVI's advanced chemistries include the PPMO, PMOplus and PMO-X.

AVI’s share price went up by 3.32% to trade at $2.18 as of 1:10 pm ET on the Nasdaq on Wednesday.

AVI is a Washington-based biopharmaceutical company specializing in the discovery and development of RNA based drugs targeting a range of diseases including influenza, duchenne muscular dystrophy, and Ebola.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.